Who owns Evommune, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
T. Rowe Price Associates, Inc.: 5.4% · 1,940,939 shares
Andera Partners: 3.9% · 1,391,990 shares — BioDiscovery 6 FPCI: 3.9% · 1,391,990 shares — Stephane Bergez: 3.9% · 1,391,990 shares
4 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Evommune, Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Evommune, Inc. they hold. Together these 131 managers report 118.96% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | $70.3M | 5,288,313 | 8.15% | 14.57% | June 30, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | $46.4M | 3,494,638 | 0.40% | 9.63% | June 30, 2026 |
129 more institutional holders behind a free account
See every manager reporting Evommune, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 111 funds hold 17.21% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund | $12.5M | 0.70% | 2.59% | June 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | $9.82M | 0.00% | 2.04% | June 30, 2026 |
109 more funds behind a free account
See every fund holding Evommune, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
